Chrysos Corporation Lifts Revenue 27% on Record Gold Assay Volumes

Chrysos Corporation Lifts Revenue 27% on Record Gold Assay Volumes

Chrysos Corporation lifts revenue 27% to $36.7m on record gold assay volumes, with 97 PhotonAssay units under contract and FY27 guidance reaffirmed.

Nik Hill
Nik HillJournalist
· 2 min read
In this storyC79
In briefAt-a-glance3 takeaways
  • 01Revenue rose 27% to $36.7m in the first four months of FY27.
  • 02Samples surged 43% to 4.91m; October hit a record 1.36m.
  • 0315 new leases signed; FY27 guidance reaffirmed.

Chrysos Corporation (ASX: C79) has lifted unaudited revenue 27% to $36.7 million in the first four months of the 2027 financial year as demand for its PhotonAssay gold-testing technology continues to grow.

Its global fleet analysed 4.91 million samples between July and October, a 43% increase on the corresponding period, while October brought a new monthly record of 1.36 million samples.

After signing 15 new lease agreements this financial year, Chrysos has 97 PhotonAssay units under contract and has reaffirmed its full-year revenue and earnings forecasts.

Chrysos has also lifted its manufacturing capacity to 18 units annually as it works towards a target of 90 deployed systems by the end of the 2029 financial year.

Growing AAC Returns

Minimum monthly assay payments contributed $22.6m, up 7%, while additional assay charges (AAC) jumped 79% to $13.7m as customers processed more samples through existing machines.

Usage-based AAC now represents 38% of PhotonAssay revenue compared with 26% a year earlier, reflecting an increasing contribution from work performed above contracted minimum volumes.

Sample processing has exceeded one million a month since March, with October throughput alone running 48% ahead of the same month last year.

“We’ve built a business model that works throughout the mining cycle—minimum monthly payments give us a secure base and, when activity is high, additional assay charges let us share in the upside,” managing director Dirk Treasure said.

“Just as importantly, the fleet, has on average sustained above 90% availability from July to October, despite many units running at very high utilisation.”

Advertisement

New Global Contracts

Eleven of the 15 lease agreements were signed after the company’s August results, including two directly with miners and nine through laboratory partners.

The growing order book sits alongside six systems deployed since the start of the financial year, bringing the operational PhotonAssay fleet to 51 units across five continents after a decommissioning in Mali.

New installations span Australia, Canada, Suriname, and Ivory Coast, taking the technology into both established mining centres and newer markets.

Another six units are being deployed, while four are awaiting installation and four remain in storage or are being prepared for shipment.

Advertisement

Full-Year Outlook Remains Unchanged

For the 2027 financial year, revenue guidance remains at $108m to $118m and EBITDA are forecast at $35m to $42m on a constant-currency basis.

The company held $19.5m in cash at 31 October and had $120m undrawn under its $200m syndicated debt facility.

That gives it a robust funding position to support the manufacture and installation of the growing number of contracted machines.

For Chrysos, the immediate task is to convert its contracted pipeline into working systems while maintaining the sample volumes that have fuelled the early-year revenue growth.

Subscribe · daily wire

Get the wire before the market opens.

The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.

Join 100,000+ investors. Unsubscribe anytime.
Nik Hill
About the author

Nik Hill

Journalist
View all articles

More like this

View all latest